Paclitaxel steady-state plasma concentration as a determinant of disease outcome and toxicity in lung cancer patients treated with paclitaxel and cisplatin

E. K. Rowinsky; M. R. Jiroutek; P. Bonomi; D. Johnson; S. D. Baker

Paclitaxel steady-state plasma concentration as a determinant of disease outcome and toxicity in lung cancer patients treated with paclitaxel and cisplatin

E. K. Rowinsky, M. R. Jiroutek, P. Bonomi, D. Johnson, S. D. Baker

Campbell University

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Clinical Cancer Research
Volume	5
State	Published - Apr 1 1999

Disciplines

Pharmacy and Pharmaceutical Sciences

Cite this

@article{f968b33f9aae46ba825c02714c57a929,

title = "Paclitaxel steady-state plasma concentration as a determinant of disease outcome and toxicity in lung cancer patients treated with paclitaxel and cisplatin",

author = "Rowinsky, {E. K.} and Jiroutek, {M. R.} and P. Bonomi and D. Johnson and Baker, {S. D.}",

year = "1999",

month = apr,

day = "1",

language = "American English",

volume = "5",

journal = "Clinical Cancer Research",

}

TY - JOUR

T1 - Paclitaxel steady-state plasma concentration as a determinant of disease outcome and toxicity in lung cancer patients treated with paclitaxel and cisplatin

AU - Rowinsky, E. K.

AU - Jiroutek, M. R.

AU - Bonomi, P.

AU - Johnson, D.

AU - Baker, S. D.

PY - 1999/4/1

Y1 - 1999/4/1

UR - https://cufind.campbell.edu/pharmacy/1486

M3 - Article

VL - 5

JO - Clinical Cancer Research

JF - Clinical Cancer Research

ER -

Paclitaxel steady-state plasma concentration as a determinant of disease outcome and toxicity in lung cancer patients treated with paclitaxel and cisplatin

Disciplines

Other files and links

Cite this